Future prospective studies incorporating serial cytokine measurements (e.g., IL-6) and tissue-based analyses are warranted to elucidate the mechanistic role of inflammatory pathways in SCLC immunotherapy resistance. The gene discussed is IL6; the disease is small cell lung carcinoma.